Business Description
Rigel Pharmaceuticals is a US-based biotech company focused on developing treatments for blood disorders and cancer. Its portfolio includes three approved drugs ? TAVALISSE, REZLIDHIA, and GAVRETO ? targeting conditions such as chronic low platelet counts, a form of leukemia, and certain thyroid and lung cancers. The company is also advancing a new oral drug, R289, through early clinical trials for a range of blood, immune, and inflammatory conditions. Founded in 1996 and based in South San Francisco, Rigel works with leading research institutions, including MD Anderson Cancer Center, to expand the use of its treatments across additional cancer types.
